ISTA Pharmaceutical announced today that a recently concluded pilot study suggests that the topical nonsteroidal anti-inflammatory (NSAID) eye drop branded XIBROM (bromfenac ophthalmic solution)(R) 0.09%, administered twice daily, may have an additive effect when used with intravitreal LUCENTIS(R) (ranibizumab injection) in reducing retinal thickness in neovascular age-related macular degeneration (NV AMD).

Among other outcomes, in terms of macular thickness, the combination of Xibrom and Lucentis showed an 81um reduction compared to a 41um reduction for Lucentis alone.

ISTA’s release notes that, historically, a change of 50um or more has been the minimum clinical meaningful change and, although this is not mirrored by an increase in visual acuity, it suggests that the use of Xibrom as an adjunctive therapy with Lucentis may benefit subjects through the reduction in complications and retinal bleeding associated with NV AMD.

Click here ^[1] to read the full release.